Relationship between alirocumab, PCSK9 and LDL-C levels:...

Atherosclerosis 2014 / 08 Vol. 235; Iss. 2

Relationship between alirocumab, PCSK9 and LDL-C levels: results from the odyssey mono phase 3 trial of alirocumab 75 mg every 2 weeks

Farnier, M., Kastelein, J.J.P., Roth, E., Taskinen, M.R., Ginsberg, H.N., Colhoun, H.M., Robinson, J.G., Merlet, L., Brunet, A., Pordy, R., Baccara-Dinet, M.T.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
235
Language:
english
Journal:
Atherosclerosis
DOI:
10.1016/j.atherosclerosis.2014.05.070
Date:
August, 2014
File:
PDF, 324 KB
english, 2014
Conversion to is in progress
Conversion to is failed